We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02293850
Recruitment Status : Unknown
Verified August 2018 by Oncolys BioPharma Inc.
Recruitment status was:  Recruiting
First Posted : November 18, 2014
Last Update Posted : August 20, 2018
Medigen Biotechnology Corporation
Information provided by (Responsible Party):
Oncolys BioPharma Inc

Brief Summary:
This is an open labeled, multiple centers, two countries (Taiwan and Korea) non-comparative phase I trial in patients with hepatocellular carcinoma. In phase I part, a maximum of 18 patients will be recruited in this study.

Condition or disease Intervention/treatment Phase
Carcinoma, Hepatocellular Biological: OBP-301 Phase 1

Detailed Description:

After screening, each eligible patient will undergo a treatment of OBP-301 within 14 days and will automatically enter follow-up period.

The follow-up period is up to 12 weeks after the last injection in the phase I part.

Each patient will return for follow-up visit weekly in the first month after the last injection, and then every 4 weeks up to the end of follow-up period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma
Actual Study Start Date : October 2014
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : April 2021

Arm Intervention/treatment
Experimental: single intra-tumoral injection
OBP-301 ; Cohort 1: 1x10 10 viral particle (VP)/ tumor Cohort 2: 1x10 11 viral particle (VP)/ tumor Cohort 3: 1x10 12 viral particle (VP)/ tumor
Biological: OBP-301
A range of dose levels is investigated and the starting dose is 1x1010 VP/tumor. Dose administration will be conducted through a dose-escalating scheme from 1x1010 VP/tumor to 1x1011 VP/tumor, 1x1012 VP/tumor, 3x1011 VP/tumor and 3x1012 VP/tumor.

Primary Outcome Measures :
  1. Evaluation of safety parameters (adverse events, laboratory data, EKG, body weight, vital signs) on patient-base. [ Time Frame: 14 weeks ]

Secondary Outcome Measures :
  1. Maximum Tolerated Dose (MTD)/ Maximum Feasible Dose (MFD) for patients using OBP-301. [ Time Frame: 16 weeks ]
  2. Dose-Limiting Toxicity (DLT) for patients using OBP-301. [ Time Frame: 28 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients aged 18 to 65 years (19 to 65 years in Korea), either sex
  2. Patients diagnosed with hepatocellular carcinoma. The diagnosis of HCC (hepatocellular carcinoma) should be established by cytology or histopathology
  3. Patients who have unresectable HCC and meet all of the following conditions:

    • Barcelona Clinic Liver Cancer (BCLC) stage B or C
    • TransAarterial ChemoEmbolization (TACE) refractory in discretion of the investigators, or TACE unsuitable (such as but not limited to portal vein thrombosis)
    • Local ablative treatment (such as percutaneous ethanol injection, radiofrequency ablation, etc) unsuitable
    • Sorafenib failure, intolerable or ineligible
  4. Patients must have at least one lesion that can be accurately measured in at least one dimension as 1 cm or more and the lesion must be suitable for repeat measurement
  5. Patients who have Child-Pugh's Score no greater than 7, and have no ascites
  6. Patients who have all the conditions below at screening:

    serum ALT (Alanine Aminotransferase) level (GPT) less than 2.5 x UNL

    • serum AST (Aspartate Aminotransferase) level (GOT) less than 2.5 x UNL
    • WBC (white blood cell) greater than or equal to 3,000 / microliter
    • Serum creatinine less than or equal to 1.5 x UNL
    • activated partial thromboplastin time (APTT) <1.5 x UNL
  7. Platelet count correctable to greater than or equal to 80,000 / microliter
  8. prothrombin time-international normalized ratio (PT-INR) correctable to less than 1.5
  9. Patients who have life expectancy longer than 12 weeks

Exclusion Criteria:

  1. Patients who have had chemotherapy within last three weeks (6 weeks for nitrosourea or Mitomycin-C) prior to dosing
  2. Patients who have had radiotherapy to tumor site within the last four weeks prior to dosing and with documentation of subsequent tumor growth at this site
  3. Patients who have received other investigational or antineoplastic medication within the last four weeks prior to dosing
  4. Patients who had history of esophageal variceal bleeding within eight weeks prior to study entry
  5. Patients who have uncontrolled diabetes, active or chronic infection, including HIV, except for asymptomatic bacterial colonization, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection
  6. Patients who had acute viral infection syndrome diagnosed within the last two weeks
  7. Patients who have concomitant hematological malignancy (e.g. acute lymphocytic leukemia, non-Hodgkin's lymphoma)
  8. Patients who have active rheumatoid arthritis or other autoimmune disease.
  9. Patients who have current requirement for chronic systemic immunosuppressive medication including any dose of glucocorticoid or cyclosporin, or chronic use of any such medication within the last four weeks Note: Course of glucocorticoid therapy less than 10 days duration is allowed (e.g. for nausea control)
  10. Patients with organ transplants (may require prolonged immunosuppressive therapy)
  11. Patients who had prior participation in any research protocol which involved administration of adenovirus vectors
  12. Patients received any immune-related related related related related blood products, such as immunoglobulin in the prior 3 months
  13. Patients who have uncontrolled concurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  14. Psychiatric, addictive, or any disorder which compromises ability to give truly informed consent for participation in this study or adequate compliance
  15. Female patients that are pregnant or on breast-feeding
  16. Patients who receive anti-platelet agents or anti-coagulation agents (e.g. Heparin, warfarin, aspirin, ticlopidine, clopidogrel, dipyridamole and so on).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02293850

Layout table for location contacts
Contact: Yira Bermudez, PhD, MBA, RAC 15514442576 y.bermudez@oncolys.com

Layout table for location information
Korea, Republic of
Pusan National University Hospital Recruiting
Busan, Korea, Republic of, 602-739
Contact: Jeong Heo         
National Taiwan University Hospital Recruiting
Taipei, Taiwan, 10002
Contact: Pei-Jer Chen         
Sponsors and Collaborators
Oncolys BioPharma Inc
Medigen Biotechnology Corporation
Layout table for investigator information
Study Chair: Pei-Jer Chen, M.D., Ph.D. National Taiwan University Hospital
Layout table for additonal information
Responsible Party: Oncolys BioPharma Inc
ClinicalTrials.gov Identifier: NCT02293850    
Other Study ID Numbers: CT-OT-21
First Posted: November 18, 2014    Key Record Dates
Last Update Posted: August 20, 2018
Last Verified: August 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases